Wu Pharmaceutic (00013.HK) will announce the key Phase II study data of Favirgleratinib for the treatment of intrahepatic cholangiocarcinoma at the European Oncology Society Gastrointestinal Tumor Congress in 2026.

The Zhitong Finance APP learned that Hutchison China MediTech (00013.HK) has announced that the results of the pivotal Phase II registration study of surufatinib (HMPL-453) for the treatment of patients with intrahepatic cholangiocarcinoma will be presented at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer Conference, taking place in Munich, Germany from July 1st to July 4th, 2026.